Thirty Madison Vaults to Unicorn Status, Raises $140 Million
(Bloomberg) -- Thirty Madison, a health-care startup that specializes in treating chronic conditions, has raised $140 million in funding, valuing the company at more than $1 billion and granting it so-called unicorn status.
HealthQuest Capital led the funding round, which included participation by Mousse Partners and Bracket Capital, as well existing backers Polaris Partners, Johnson & Johnson Innovation - JJDC Inc., Greycroft and Northzone.
“The new funding will allow us to drive better patient experiences and superior health outcomes at a scale that hasn't previously been possible,” Chief Executive Officer Steven Gutentag said in an interview.
In 2020, Thirty Madison's revenue tripled, and in the first quarter of 2021, sales surpassed an annual run-rate of $100 million, Gutentag said. Thirty Madison's personalized treatment and chronic condition-management tools, including medication and ongoing communication with a physician, are used by by more than 250,000 active customers.
Founded in 2017 by Gutentag and Demetri Karagas, Thirty Madison operates four verticals: Keeps, Cove, Evens and Picnic, which specialize in men's hair loss, migraines, gastrointestinal conditions and allergies, respectively.
“In the next couple of years we want to have at least one brand that's relevant to every single person in the country,” Gutentag said, citing heart disease, diabetes, dermatological conditions, sleep, mental health and metabolism as other potential avenues.
Thirty Madison's telemedicine service reaches more than 40 U.S. states, and pharmacy offerings are available nationwide, he said. The company has long-term ambitions to launch internationally.
“With Covid, the move toward telemedicine has been very dramatic,” said HealthQuest Capital partner Randy Scott, who is joining Thirty Madison's board. “Acceptance by the consumer and patient population of alternative-care models has resulted in ten years' worth of change in 18 months.”
Read more: Online Pharmacy Ro Is Said to Raise Funds at $5 Billion Value
The company competes against telemedicine providers such as Teladoc Health Inc., Livongo and Omada Health, as well as online pharmacies Ro and Hims & Hers Health Inc. Hims & Hers became a public company through a SPAC merger.
“I don't have a particular view on whether a SPAC is right for us,” Gutentag said. “But the more ways there are for good companies to enter the public markets or get financing -- it's certainly not a bad thing.”
Thirty Madison has about 180 employees, more than triple its workforce at the start of the pandemic. Its hires include President Michelle Carnahan, a former Sanofi SA and Eli Lilly & Co. executive; and Jason Rubin, a Walgreens veteran.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.